(Q36432836)

14 August 2017

1 reference

title

Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer (English)

1 reference

14 August 2017

1 reference

1 reference

Nicolas Mottet

1

1 reference

14 August 2017

Tommaso Prayer-Galetti

2

1 reference

14 August 2017

Peter Hammerer

3

1 reference

14 August 2017

Michael W Kattan

4

1 reference

14 August 2017

Ulf Tunn

5

1 reference

14 August 2017

publication date

23 March 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

98

1 reference

14 August 2017

issue

1

1 reference

14 August 2017

page(s)

20-27

1 reference

The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Androgen deprivation therapy for prostate cancer: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Complementary and alternative therapies for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Effective testosterone suppression for patients with prostate cancer: is there a best castration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

An investigation into the use of palliative care services by patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Osteoporosis in men treated with androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Insulin, physical activity, and caloric intake in postmenopausal women: breast cancer implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Risk factors for male osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Management of Bone Loss in Men With Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Role of bisphosphonates in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Quality of life issues relating to endocrine treatment options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Intermittent androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Intermittent androgen suppression in prostate cancer: the Canadian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Intermittent androgen suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Fetoscopic placement of a transurethral stent for intrauterine obstructive uropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

A 10-year clinical experience with intermittent hormonal therapy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

Intermittent androgen suppression in the treatment of metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

The Effects of Combined Androgen Blockade on Cognitive Function During the First Cycle of Intermittent Androgen Suppression in Patients With Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

HIP FRACTURES IN MEN WITH PROSTATE CANCER TREATED WITH ORCHIECTOMY

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06176.X

10.1111/J.1464-410X.2006.06176.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference